Prasugrel Tablet, Film Coated
Product Images NDC 51407-444

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Prasugrel (NDC 51407-444). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-444-30lb.jpg (51407 444 30lb)

Prasugrel 5 mg film-coated tablets label from Golden State Medical Supply, Inc. The label indicates 30 tablets per container with NDC 51407-444-30. It includes usage instructions, storage conditions, and warnings about tampering. The packaging is marked Rx only.*

FDA Label Image

51407-445-30lb.jpg (51407 445 30lb)

Prasugrel 10 mg film-coated tablets packaging label showing 30 tablets per bottle. The label includes the NDC number 51407-445-30, the active ingredient prasugrel, and indicates prescription use only. It is labeled by Golden State Medical Supply, Inc. Additional instructions and storage conditions are printed on the label.*

FDA Label Image

Figure 1: Non-cabg-related Timi Major Or Minor Bleeding Events. (Image 01)

A line graph comparing the incidence of non-CABG-related TIMI major or minor bleeding events (%) in patients taking Prasugrel versus Clopidogrel over a period of up to 450 days from randomization. The graph includes a secondary smaller plot within the main graph showing the early phase from 0 to 7 days.*

FDA Label Image

Prasugrel Hydrochloride Structural Formula (Image 02)

Chemical structure of Prasugrel hydrochloride, showing the molecular arrangement with chemical bonds and functional groups including a cyclopropyl group, fluorophenyl ring, tetrahydrothieno ring, and ester moiety.*

FDA Label Image

Figure 2: Inhibition (mean ± Sd) Of 20 μm Adp-induced Platelet Aggregation (ipa) Measured By Light Transmission Aggregometry After Prasugrel 60 mg. (Image 03)

A line graph depicting the inhibition of platelet aggregation (%) over time (hours). The graph shows data points with error bars representing mean ± SD at various time intervals up to 24 hours, assessing the effect of 20 µM ADP on platelet aggregation inhibition.*

FDA Label Image

Figure 3: Time To First Event Of Cv Death, Mi, Or Stroke (triton-timi 38). (Image 04)

Two line graphs depicting cardiovascular death, nonfatal myocardial infarction (MI), or nonfatal stroke (%) over days from randomization. The upper graph compares outcomes in UA/NSTEMI patients using Prasugrel Tablets versus Clopidogrel. The lower graph shows similar data for STEMI patients. In both graphs, Prasugrel demonstrates lower event rates than Clopidogrel over approximately 450 days, with insets focusing on the first 7 days.*

FDA Label Image

Figure 4: Subgroup Analyses For Time To First Event Of Cv Death, Mi, Or Stroke (hr And 95% Ci; Triton-timi 38) – Ua/nstemi Patients. (Image 05)

A forest plot chart comparing baseline characteristics and percent events for prasugrel and clopidogrel tablet groups. It includes hazard ratios for various subgroups such as age, gender, body weight, region, diabetes, metabolic syndrome, previous cardiovascular events, time from symptom onset, stent type, and use of GP IIb/IIIa inhibitors. The chart visually contrasts the relative risk between prasugrel and clopidogrel treatments across these categories.*

FDA Label Image

Figure 5: Subgroup Analyses For Time To First Event Of Cv Death, Mi, Or Stroke (hr And 95% Ci; Triton-timi 38) – Stemi Patients. (Image 06)

A hazard ratio forest plot comparing percent events between Prasugrel and Clopidogrel tablets at 10 mg and 12.4 mg doses across various baseline characteristics such as age, gender, body weight, geographic region, diabetes mellitus, metabolic syndrome, previous myocardial infarction, previous PCI, previous CABG, previous TIA/stroke, time from symptom onset, stent type, and GP IIb/IIIa inhibitor use. The plot displays hazard ratios with confidence intervals indicating whether Prasugrel or Clopidogrel is favored for each subgroup.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.